Pharmaceutical/Biotech Mergers & Acquisitions Expected to Continue


I ran across this interesting article about a significant trend in the pharmaceutical and biotech industry.

http://bloom.bg/PCltx4

In a nutshell, drug makers are shifting their focus from cutting costs to filling pipelines through mergers and acquisitions. Next year could top the 2,076 deals worth $166 billion announced in the past 12 months. “What tends to drive that is the need. There’s clearly a need for larger companies who are facing patent cliffs and whose own R&D machines have not panned out, to find growth.”

The extremely high cost of bringing new drugs to market is one of the primary factors for this increase in partnerships, mergers and acquisitions in healthcare. The chart below shows the spending for top 10 firms and represents a whopping $66 Billion annual investment.

Research Spending Per New Drug

Company Ticker # of drugs approved R&D spending per drug ($M) Total R&D Spend 1997-2011 ($M)
AstraZeneca AZN 5 11,791 58,955
GlaxoSmithKline GSK 10 8,171 81,708
Sanofi SNY 8 7,909 63,274
Roche Holdings AG RHH 11 7,804 85,841
Pfizer, Inc. PFE 14 7,727 108,178
Johnson & Johnson JNJ 15 5,886 88,285
Eli Lilly & Co. LLY 11 4,577 50,347
Abbott Laboratories ABT 8 4,496 35,970
Merck & Co. Inc. MRK 16 4,210 67,360
Bristol-Myers Squibb Co. BMY 11 4,152 45,675

Sources: InnoThink Center For Research In Biomedical Innovation; Thomson Reuters Fundamentals via FactSet Research Systems

Cost cutting can only go so far before it negatively affects the growth of any company. Since 2000, the pharmaceutical industry has cut 297,650 jobs, according to consulting firm Challenger, Gray & Christmas. These companies are finding that a shift from cutting costs to making agreements can more effectively help build product lines.

Nearly half of today’s top-selling drugs are the result of partnerships. Companies that excel in business development and alliance management position themselves to win new deals. Those organizations that show a penchant for successful collaborations will attract other companies looking for strong allies — in the process filling critical portfolio holes and penetrating exciting new markets.

A major challenge with business development and alliance management are the majority of pharmaceutical and biotechnology companies today have legacy CRM tools or home grown systems that have not been able to keep up with this rapid pace of change in the market. These traditional and legacy solutions have become much too inflexible and too costly to maintain, leaving pharmaceutical companies in the unenviable position of overspending every day on solutions that no longer meet their business requirements.

Infinity has developed the Infinity iPartner platform that is designed for the pharmaceutical and biotechnology partnering life cycle. Infinity iPartner puts everything in one place for your teams to track and coordinate the finding, partnering, deal management, obligations, payments, milestones and other key activities required for managing an increasingly complex network of partners. All on a modern and highly flexible platform that is easier to use and maintain than existing systems and processes.

ipartner-dashboard-sm

To learn more about Infinity iPartner powered by Microsoft Dynamics CRM, contact us today.

Advertisements
Posted in CRM, Life Sciences, Partnering, Pharma

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Sponsors
%d bloggers like this: